Stroke Prevention: Carotid Stenosis Management and Dual Antiplatelet Therapy Evidence
Symptomatic Carotid Stenosis: CEA, CAS, or Medical Therapy
For symptomatic carotid stenosis ≥50% (NASCET criteria), carotid endarterectomy (CEA) remains the reference standard, supported by NASCET and ECST demonstrating a 17% absolute risk reduction in stroke at 2 years for 70-99% stenosis (NNT 6). The CREST trial showed equivalent 30-day stroke/death/MI rates for CEA and carotid artery stenting (CAS) overall (6.8% vs 7.2%), but a higher periprocedural stroke rate with CAS (4.1% vs 2.3%) and higher MI rate with CEA (2.3% vs 1.1%). Ten-year follow-up confirmed equivalent long-term outcomes. Age modifies the treatment effect: patients under 70 trend toward equivalent or better outcomes with CAS, while those over 70 have lower periprocedural risk with CEA.
Asymptomatic Carotid Stenosis: The Evolving Debate
The CREST-2 trial was designed to answer whether revascularization (CEA or CAS) added to intensive medical therapy is superior to intensive medical therapy alone for asymptomatic stenosis ≥70%. The medical arm in CREST-2 reflects modern best practice: high-intensity statin, antiplatelet therapy, blood pressure control (<130/80 mmHg), diabetes management, and smoking cessation. Historical trials (ACAS, ACST) showed a modest benefit for CEA but were conducted before the era of aggressive medical management. Annual stroke risk with modern medical therapy for asymptomatic stenosis is now estimated at 0.5-1.0% per year, compared to the 2% per year observed in the medical arms of ACAS/ACST.
Dual Antiplatelet Therapy: CHANCE and POINT Trials
The CHANCE trial (5,170 Chinese patients with minor stroke or high-risk TIA) showed that aspirin plus clopidogrel for 21 days followed by clopidogrel monotherapy reduced 90-day stroke recurrence from 11.7% to 8.2% (HR 0.68, 95% CI 0.57-0.81). The POINT trial (4,881 international patients) confirmed the benefit of aspirin plus clopidogrel started within 12 hours of minor stroke/TIA, with a 25% reduction in major ischemic events at 90 days (HR 0.75, 95% CI 0.59-0.95), but increased major hemorrhage when DAPT was continued beyond 21 days. The combined message: time-limited DAPT (21 days) provides the optimal risk-benefit balance.
Sponsored
Ticagrelor in Stroke Prevention: THALES Trial
The THALES trial compared aspirin plus ticagrelor (180 mg load, then 90 mg BID for 30 days) versus aspirin alone in minor stroke/TIA. The combination reduced 30-day stroke or death from 6.6% to 5.5% (HR 0.83, 95% CI 0.71-0.96), with an increase in severe bleeding (0.5% vs 0.1%). Ticagrelor-based DAPT may be considered when clopidogrel resistance is suspected (CYP2C19 loss-of-function alleles present in 25-30% of populations) or when rapid onset of antiplatelet effect is needed, given ticagrelor's faster pharmacodynamic profile compared to clopidogrel.
Long-Term Secondary Prevention
After the initial 21-30 day DAPT window, long-term secondary prevention consists of single antiplatelet therapy (aspirin 81 mg or clopidogrel 75 mg), high-intensity statin (targeting LDL <70 mg/dL, with the TST trial showing benefit from targeting LDL <70 vs 90-110 mg/dL), and blood pressure control (<130/80 mmHg per SPRINT data extrapolation, with the SPS3 trial supporting <130 systolic in lacunar stroke). For patients with embolic stroke of undetermined source (ESUS), the NAVIGATE ESUS and RE-SPECT ESUS trials showed no benefit of rivaroxaban or dabigatran over aspirin, maintaining aspirin as the default antiplatelet for non-cardioembolic stroke. AF screening with prolonged cardiac monitoring (30-day event recorder or implantable loop recorder) is recommended in cryptogenic stroke, with the CRYSTAL-AF trial showing AF detection in 30% with implantable monitoring at 3 years.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.